ARC101 in Advanced Solid Tumors

Eligibility Criteria

• * Locally advanced or metastatic solid tumor ovarian, testicular or other Claudin 6+ cancers
• * Measurable or evaluable disease, per RECIST v1.1
• * Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• * Adequate organ function
• * Active CNS involvement
• * Malignancy diagnosis other than the disease under study within 2 years prior to the first dose of study drug.
• * Presence of uncontrolled ascites
• * Toxicity related to prior anticancer therapy that has not returned to Grade ≤1 or baseline levels
• * Clinically significant pulmonary compromise
• * Active autoimmune disease within 12 months prior to first dose of study drug.
• * Female participant who is pregnant, breastfeeding, or plans to become pregnant or male participant who plans to father a child either while enrolled or within 90 days after the final administration of study drug.